Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET - sprookjes - yvandenbroek - TriplyDB

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

http://www.wikidata.org/entity/Q34041370

about

Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.(18)F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application.Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.Novel positron emission tomography tracer distinguishes normal from cancerous cells.Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities.Targeting the de novo biosynthesis of thymidylate for the development of a PET probe for pancreatic cancer imaging.

P2860

Q26778463-FFD76BE8-EE74-4A4F-B9FA-0F94E761D9ED Q28487987-7F216EE4-00AE-4F2C-9B54-DFDBE971968C Q30757279-A734AF5E-3499-4111-B0F6-B82C8629702C Q33912335-02CF7132-3581-4CF1-9DC9-8C9242A0D188 Q34998377-26506B2E-59B6-4C4D-9CCC-2AEAD10D1D24 Q35463464-82EB328E-DD3D-465A-A2E9-402FFCCF2B72 Q36228895-501B2034-C99C-42FB-ACE8-2A50EFFD97A1 Q36533822-D76C4FB6-8869-4754-B435-4E1E58AF9802 Q36894808-126BBF52-E5AC-4451-AE48-A4F54F610129 Q37474422-317410EB-0398-4E7D-A2B5-C9C23BB1A24B Q38673771-B9B8B9A0-0A4F-4914-AF33-F03000FD7EA7 Q38775709-C8451DB2-9C31-40C1-A2C2-C3F52E29C4FC Q39053500-162773BA-F005-493E-BF27-737079808A2D Q42555617-B4E6D8F7-AF0B-463F-B759-105EE9947DFC

P2860

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

http://www.wikidata.org/entity/Q34041370

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@ast

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@en

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@nl

type

label

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@ast

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@en

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@nl

prefLabel

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@ast

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@en

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@nl

P1433

Q34041370-E4DF3B74-3B29-4CC6-B399-8313D6F25CAD

P1476

Q34041370-FF0E9498-4E77-42E7-B93F-0059257DE8C0

P2093

Q34041370-039C49CF-2DA9-4D7B-8283-F0ED4291E75A

Q34041370-068FB985-DF3B-4D07-9FD0-2792EFB5182F

Q34041370-093C654B-DADB-489C-B7D2-E1D6DB8A9EF4

Q34041370-0DF36EE8-0F04-4384-B31B-A1CA12A0DE6C

Q34041370-139A73E4-9823-4846-9906-449F183025DF

Q34041370-1BC9BF7B-F3C3-43C6-AA18-3F1133F3A02A

Q34041370-5EFB288A-C043-496D-8D51-860E9C0415BA

Q34041370-DECB79F5-A9C9-4026-AA0D-40D358BE7D93

Q34041370-E8AE03A9-E709-4991-9FB3-B90F08F43DCC

Q34041370-F14F1E83-0DE3-4992-8D59-81656DB30726

P2860

Q34041370-106BF15C-C562-4C8E-A9A7-E11A39B6E384

Q34041370-1FFB61CD-55E6-49D2-956B-9BDDEA318433

Q34041370-20A9099F-0F92-4AE6-BC8F-42F579175C7D

Q34041370-2B3719E6-387B-469C-80B0-E150A3DBAD94

Q34041370-34FFA670-897E-4B11-B554-C3B17D437845

Q34041370-44BD18F5-EE55-4E4F-A2D2-3D83D8E91A4C

Q34041370-4803B4DA-71EE-4FF0-A798-05877049D6EF

Q34041370-49540EA4-7701-4967-9675-9F879A326E8E

Q34041370-4F802E06-6415-4668-9E3B-E1E63BFD1D23

Q34041370-502EE854-9CB2-45B6-85D5-B2FB9A878DC0

P304

Q34041370-334E41A7-1781-447A-89D4-55F6424B4094

P31

Q34041370-F7D4C1B2-5214-45D9-A441-AED4365911EE

P356

Q34041370-D3AAF0CD-BD91-454B-A973-93C9642F3A76

P433

Q34041370-A47003FE-921C-4FFF-8832-C70D69FB45E9

P478

Q34041370-C8DB906A-6D24-4711-AD01-DFCF46ADD3BA

P50

Q34041370-E2757211-7DDD-477A-B4BB-934D6119E658

P577

Q34041370-AEA14D10-6E1A-47F4-BABB-1B6F09B8D08A

P5875

Q34041370-BDC68B06-7E4A-4758-B6D2-C4B854D52880

P698

Q34041370-9E75FCEA-C517-407B-A719-FB8182579BEE

P932

Q34041370-341A2C7B-A5C1-43EA-B417-9D39EBDD359F

P356

P1433

Translational Oncology

P1476

Anti-Angiogenic/Vascular Effec ...... Not Detectable by FDG/FLT-PET

@en

P2093

Catherine Cannet

http://www.w3.org/2001/XMLSchema#string

Heidi A Lane

http://www.w3.org/2001/XMLSchema#string

Melanie Sticker-Jantscheff

http://www.w3.org/2001/XMLSchema#string

Michael Honer

http://www.w3.org/2001/XMLSchema#string

Michael Stumm

http://www.w3.org/2001/XMLSchema#string

Mike Becquet

http://www.w3.org/2001/XMLSchema#string

Paul Mj McSheehy

http://www.w3.org/2001/XMLSchema#string

Peter R Allegrini

http://www.w3.org/2001/XMLSchema#string

Pius A Schubiger

http://www.w3.org/2001/XMLSchema#string

Simon M Ametamey

http://www.w3.org/2001/XMLSchema#string

P2860

The TOR pathway: a target for cancer therapy

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle.

Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Targeting angiogenesis with oral agents.

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

P304

264-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/TLO.10127

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45509148

http://www.w3.org/2001/XMLSchema#string

P698

20689768

http://www.w3.org/2001/XMLSchema#string

P932

2915418

http://www.w3.org/2001/XMLSchema#string